ONCY - Oncolytics Biotech Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.31
+0.06 (+1.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.25
Open4.16
Bid4.31 x 1200
Ask7.21 x 800
Day's Range4.16 - 4.40
52 Week Range3.61 - 8.55
Volume19,212
Avg. Volume66,319
Market Cap72.481M
Beta0.47
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    Oncolytics Biotech® Reports 2018 Second Quarter Results

    CALGARY, Alberta and SAN DIEGO, Aug. 03, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced financial ...

  • GlobeNewswire19 days ago

    Oncolytics Biotech® to Present at the Canaccord Genuity 38th Annual Growth Conference

    CALGARY, Alberta and SAN DIEGO, July 31, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that ...

  • Zacks Small Cap Research2 months ago

    ONCY: It Has Been a Busy Week or Two

    Over the last week or so, Oncolytics (ONCY) (ONC.TO) has experienced a flurry of activity from announcing a research collaboration with the Keck School of Medicine, to raising additional cash in preparation for their Phase III trial. Oncolytics also presented at the ASCO conference discussing a poster highlighting biomarkers that are predictive of response by checkpoint inhibitors. Since our update on the quarter, Oncolytics forged a collaboration with the Keck School of Medicine at USC to examine the use of their lead candidate pelareorep in combination with Keytruda, Velcade and dexamethasone for multiple myeloma.

  • GlobeNewswire2 months ago

    Oncolytics Biotech® Closes USD $8.9 Million Public Offering of Common Shares

    Oncolytics Biotech® Inc. (ONC.TO) (ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced the closing of its previously announced underwritten public offering of 1,532,278 common shares, including 160,065 common shares pursuant to the exercise of the underwriters’ option to purchase additional common shares (the “Offering”). The gross offering proceeds to the Company from this Offering are approximately USD $8.9 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering was made pursuant to a U.S. registration statement on Form F-10, declared effective by the United States Securities and Exchange Commission (the “SEC”) on May 7, 2018 (the “Registration Statement”), and the Company’s existing Canadian short form base shelf prospectus (the “Base Shelf Prospectus”) dated May 4, 2018.

  • GlobeNewswire2 months ago

    Oncolytics Biotech® Announces Poster Presentation Demonstrating the Ability of REOLYSIN® to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting

    CALGARY, Alberta and SAN DIEGO, June 04, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced a ...

  • GlobeNewswire3 months ago

    Oncolytics Biotech® Announces Listing on Nasdaq Capital Market

    CALGARY, Alberta and SAN DIEGO, June 01, 2018-- Oncolytics Biotech ® Inc., currently developing REOLYSIN ®, an intravenously delivered immuno-oncolytic virus turning cold tumors hot, today announced that ...